A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/ cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: A randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)

Annals of Oncology

Volumn 17, Issue 7, 2006, Pages 1111-1119

  Booton, R ^a   Lorigan, Paul ^a   Anderson, H ^b   Baka, S ^a   Ashcroft, L ^a   Nicolson, M ^c   O'Brien, M ^d   Dunlop, D ^e   O'Byrne, K ^f   Laurence, V ^g   Snee, M ^h   Dark, G ⁱ   Thatcher, N ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b WYTHENSHAWE HOSPITAL   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^f ST JAMES S HOSPITAL   (Ireland)

^g POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^h Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

ⁱ NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Docetaxel; Lung cancer; Quality of life

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; IFOSFAMIDE; MITOMYCIN C; VINBLASTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL ANALYSIS; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR BIOPSY; VOMITING;

EID: 33745632406     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl078     Document Type: Article

References (43)

1. Shibuya K, Mathers CD, Boschi-Pinto C et al. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002; 2: 37.
2. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Brit Med J 1995; 311: 899-909.
3. Marino P, Pampallona S, Preatoni A et al. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-865.
4. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
5. Spiro S, Rudd R, Souhami R et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer; improved survival without detriment to quality of life. Thorax 2004; 59: 828-836.
6. Brown J, Thorpe H, Napp V et al. The Big Lung Trial Quality of Life Study: Determining the effect of cisplatin based chemotherapy for supportive care patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22: Abstr 2533.
7. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-157.
8. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer 2000; 83: 447-453.
9. Elderly Lung Cancer Vinorelbine Italian Study Group T. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. JNCI Cancer Spectrum 1999; 91: 66-72.
10. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
11. Giannakakis T, Ziras N, Kouroussis C et al. Phase I/II study of docetaxel and carboplatin as first line chemotherapy in advanced NSCLC. Proc Am Soc Clin Oncol 1998; Abstr 1870.
12. Belani CP, Einzig A, Bonomi P et al. Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer. Ann Oncol 2000; 11: 673-678.
13. Millward MJ, Boyer MJ, Lehnert M et al. Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in Caucasian and Asian patients. Ann Oncol 2003; 14: 449-454.
14. Danson S, Middleton M, O'Byrne K et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with advanced non-small cell lung cancer. Cancer 2003; 98: 542-553.
15. Crino L, Scagliotti GV, Ricci S et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17: 3522-3530.
16. Rudd R, Gower N, Sprio S et al. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer. J Clin Oncol 2005; 23: 142-153.
17. Belani C, Lee J, Socinski M et al. Randomised phase III trial comparing cisplatinetoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 2005; 16: 1069-1075.
18. Besse B, Soria J, LeChevalier T. Front-line doublets in advanced non-small cell lung cancer; the golden age for second line chemotherapy. Ann Oncol 2005; 16: 997-998.
19. Paccagnella A, Favaretto A, Oniga F et al. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung. A multicentre, randomised phase III trial. Lung Cancer 2004; 43: 83-91.
20. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
21. Kelly K, Crowley J, Bunn PA Jr et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 2001; 19: 3210-3218.
22. Fossella F, Pereira JR, von Pawel J et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003; 21: 3016-3024.
23. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002; 20: 4285-4291.
24. Kubota K, Watanabe K, Kunitoh H et al. Phase III trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer; the Japanese Taxotere Lung Cancer Study Group. J Clin Oncol 2004; 22: 254-261.
25. Rosell R, Gatzemeier U, Betticher D et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced nonsmall-cell-lung cancer; a cooperative multinational trial. Ann Oncol 2002; 13: 1539-1549.
26. Smit EF, van Meerbeeck JP, Lianes P et al. Three-arm randomised study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced nonsmall-cell lung cancer; a phase III trial of the European Organisation for Research and Treatment of Cancer Lung Cancer Group- EORTC 08975. J Clin Oncol 2003; 21: 3909-3917.
27. Georgoulias V, Papadakis E, Alexopoulos A et al. Platinum based versus nonplatinum chemotherapy in non-small cell lung cancer. Lancet 2001; 357: 1478-1484.
28. Kosmidis P, Mylonakis N, Nicolaides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer. A phase IV randomised trial. J Clin Oncol 2002; 20: 3578-3585.
29. Gridelli C, Gallo C, Shepherd F et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer; A phase III trial of the Italian GEMVIN Investigators and the National Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21: 3025-3034.
30. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin based triplet versus a nonplatinum sequential doublet in advanced non-small cell lung cancer. A Spanish lung cancer research group phase III randomised trial. J Clin Oncol 2003; 21: 3207-3213.
31. Laak E, Dickgreber N, Muller T et al. Randomised phase III study of gemcitabine and vinorelbine versus gemcitabine, vinorelbine and cisplatin in advanced nonsmall cell lung cancer; from the German and Swiss lung cancer study group. J Clin Oncol 2004; 22: 2348-2356.
32. Georgoulias V, Ardavanis A, Tsiafaki X et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small cell lung cancer J Clin Oncol 2005; 23 [online publication 10.1200/JCO.2005.04.016]
33. Stathopoulos G, Veslemes M, Georgatou N et al. Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell-lung cancer: A randomised phase III trial. Ann Oncol 2004; 15: 1048-1055.
34. Grigorescu A, Draghiei J, Nitipir C et al. Gemcitabine and carboplatin versus cisplatin and vinblastine in advanced non-small cell lung cancer stages III and IV: A randomised phase III trial. Lung Cancer 2002; 37: 9-14.
35. Souquet P, Tan E, Pereira J et al. GLOB-1: A prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small cell lung cancer. Ann Oncol 2002; 13: 1853-1861.
36. Zatloukal P, Petruzelka L, Zemanova M et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatinin stage IIIb and IV non-small cell lung cancer: A phase III randomised trial. Lung Cancer 2003; 41: 321-331.
37. Hotta K, Matsuo K, Ueoka H et al. Meta-analysis of randomised clinical trials comparing cisplatin to carboplatin in patients with advanced NSCLC. J Clin Oncol 2004; 22: 3852-3859.
38. D'Addario G, Pintilie M, Leighl N et al. Platinum-based versus non-platinum-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 2005; 23 [online publication 10.1200/JCO.2005.03.045]
39. Georgoulias V, Ardavanis A, Agelidou A et al. Docetaxel versus docetaxel plus cisplatin as front line therapy in patients with advanced non-small cell lung cancer: A randomised, multicentre phase III trial. J Clin Oncol 2004; 22: 2602-2609.
40. Hopwood P, Howell A, Maguire P. Screening for psychiatric morbidity in patients with advanced breast cancer: Validation of two self-report questionnaires. Br J Cancer 1991; 64: 353-356.
41. Billingham L, Cullen M. Potential hazards in the analysis of symptom improvement. Lung Cancer 2003; 40: 201-202.
42. Gralla R, Thatcher N. Quality of life assessment in advanced lung cancer: Considerations for evaluation in patients receiving chemotherapy. Lung Cancer 2004; 46 (Suppl 2): S41-S47.
43. Harper P, Plunket T, Khayat D. Quality trials and quality of life in non-small cell lung cancer. J Clin Oncol 2003; 21: 3007-3008.